About
Technology
Issues
FAQ
Links
Official Page
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.